Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1436]
News [2923]
Articles [126]
Editorials [5]
Conferences [154]
elearning [6]
Treating acute leukaemias of ambiguous lineage
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research...
Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )
8 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D)...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )
7 Dec 2020
PARP inhibitors in prostate cancer: A promise delivered
Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA
PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )
1 Dec 2020
Clinical genomic testing in prostate cancer
Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA
Clinical genomic testing in prostate cancer ( Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA )
24 Nov 2020
PARP inhibitors for prostate cancer - Nurse's view
Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA
PARP inhibitors for prostate cancer - Nurse's view ( Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA )
24 Nov 2020
Using circulating tumour DNA dynamics to predict outcomes in advanced cancers
Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston...
Using circulating tumour DNA dynamics to predict outcomes in advanced cancers ( Dr Mohamed Gouda - The University of Texas MD Anderson Cancer Center, Houston, USA )
23 Nov 2020
OncoAlert and ecancer weekly roundup for November 8 - 14, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for November 8 - 14, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Nov 2020
OncoAlert and ecancer weekly roundup for November 2 - 7, 2020
Dr Gil Morgan - Skåne University Hospital, Lund, Sweden
OncoAlert and ecancer weekly roundup for November 2 - 7, 2020 ( Dr Gil Morgan - Skåne University Hospital, Lund, Sweden )
9 Nov 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation